Abstract

The effectiveness of a single dose mitomycin-C instillation immediately after TUR on short-term recurrences in patients with low-risk superficial bladder tumors has been investigated in this study.

A total number of 40 patients with the diagnosis of low-risk superficial bladder cancer have been evaluated in a prospective, randomized trial. Patients with primary, single tumors 3cm or less and/or recurrent tumors which were recurrence-free in the previous year were enrolled in the study. Patients with muscular invasion, G3 tumors or carcinoma-in-situ were excluded from the study. All of the patient had a complete TUR before randomization and were divided into 2 groups: No further treatment or intracavitary single dose 40mg mitomycin-C. The follow-up period was 2 years.

After 24 months of follow-up, 6 (30%) recurrences were encountered in the control group compared to 3 (15%) recurrences in the mitomycin-C group (p=0.45). The mean time to recurrence was 6.5±3.5 months in the control group where this number was 15.0±5.2 months in mitomycin-C group (p=0.049).

Our analysis confirms the positive effect of early single dose mitomycin-C instillation in patients with low-risk superficial bladder cancer with a longer period of time to recurrence and it does not seem to change the overall recurrence rate.